Botulinum Toxin Type A for Chronic Low Back Pain .
Botulinum toxin type A for treating chronic low back pain: A double blinded randomized control study.
World J Methodol . 2024 Sep 20;14(3):93854.Forty-four patients with chronic low back pain were randomized to receive either Botulinum toxin type A (BoNT-A; n=22) or a placebo (n=22). The primary outcome was the reduction in pain, measured by the Visual Analog Scale (VAS). Secondary outcomes included disability assessed by the Oswestry Disability Index (ODI) and the safety of the intervention. Outcomes were evaluated at baseline and after 8 weeks. Overall, both groups experienced significant reductions in VAS and ODI scores. However, the reduction in ODI scores was statistically significant but clinically insignificant, and changes in VAS scores were not statistically significant. The study concluded that BoNT-A did not provide a short-term advantage over placebo for pain relief or functional improvement in chronic low back pain.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
